Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena

Clinical Cancer Research

Volumn 12, Issue 8, 2006, Pages 2385-2389

  Melero, Ignacio ^a,b   Arina, Ainhoa ^a   Murillo, Oihana ^a   Dubrot, Juan ^a   Alfaro, Carlos ^a   Pérez Gracia, Jose L ^a   Bendandi, Maurizio ^a   Hervás Stubbs, Sandra ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; INTERLEUKIN 12; TUMOR ANTIGEN;

CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL ACTIVATION; CELL BASED GENE THERAPY; CELL DEATH; CELL MATURATION; CLINICAL TRIAL; CROSS PRESENTATION; DENDRITIC CELL; HUMAN; IMMUNOGENICITY; NONHUMAN; NOTE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; DENDRITIC CELLS; IMMUNOTHERAPY, ADOPTIVE; MICE; MODELS, BIOLOGICAL; NEOPLASMS, EXPERIMENTAL;

EID: 33646433944     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0314     Document Type: Note

References (26)

1. Saji H, Song W, Furumoto K, Kato H, Engleman EG. Systemic anti-tumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy. Clin Cancer Res 2006;12:2568-74.
2. Arina A, Tirapu I, Alfaro C, et al. Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. Exploiting cross-priming. Exp Hematol 2002;30:1355-64.
3. Jung S, Unutmaz D, Wong P, et al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 2002;17:211-20.
4. Mempel TR, Henrickson SE, Von Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004;427:154-9.
5. Carbone FR, Belz GT, Heath WR. Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity. Trends Immunol 2004;25:655-8.
6. Lindquist RL, Shakhar G, Dudziak D, et al. Visualizing dendritic cell networks in vivo. Nat Immunol 2004;5:1243-50.
7. van der Most RG, Currie A, Robinson BW, Lake RA. Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res 2006;66:601-4.
8. Huarte E, Tirapu I, Arina A, et al. Intratumoural administration of dendritic cells: hostile environment and help by gene therapy. Expert Opin Biol Ther 2005;5:7-22.
9. Binder RJ, Srivastava PK. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol 2005;6:593-9.
10. Norbury CC, Basta S, Donohue KB, et al. CD8+ T cell cross-priming via transfer of proteasome substrates. Science 2004;304:1318-21.
11. Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004;200:297-306.
12. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685-711.
13. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006;7:131-7.
14. Le Bon A, Etchart N, Rossmann C, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003;4:1009-15.
15. Wilson NS, Behrens GM, Lundie RJ, et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol 2006;7:165-72.
16. Skoberne M, Beignon AS, Larsson M, Bhardwaj N. Apoptotic cells at the crossroads of tolerance and immunity. Curr Top Microbiol Immunol 2005;289:259-92.
17. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005;65:8059-64.
18. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-5.
19. Wagner H, Bauer S. All is not Toll: new pathways in DNA recognition. J Exp Med 2006;30:30.
20. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005;202:1691-701.
21. Correale P, Cusi MG, Tsang KY et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and anti-tumor activity in metastatic colon cancer patients. J Clin Oncol 2005;23:8950-8.
22. Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res 2001;61:7530-5.
23. Teitz-Tennenbaum S, Li Q, Rynkiewicz S, et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res 2003;63:8466-75.
24. Chi KH, Liu SJ, Li CP, et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 2005;28:129-35.
25. Mazzolini G, Alfaro C, Sangro B, et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 2005;23:999-1010.
26. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 1999;59:4035-41.